Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) EBT Margin (2016 - 2025)

Arrowhead Pharmaceuticals' EBT Margin history spans 16 years, with the latest figure at 10.71% for Q4 2025.

  • For Q4 2025, EBT Margin rose 701531.0% year-over-year to 10.71%; the TTM value through Dec 2025 reached 23.37%, up 2597881.0%, while the annual FY2025 figure was 6.21%, 1725375.0% up from the prior year.
  • EBT Margin reached 10.71% in Q4 2025 per ARWR's latest filing, down from 14.08% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 68.11% in Q1 2025 to a low of 7004.6% in Q4 2024.
  • Average EBT Margin over 5 years is 813.05%, with a median of 165.54% recorded in 2021.
  • Peak YoY movement for EBT Margin: plummeted -383881bps in 2023, then skyrocketed 701531bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 229.13% in 2021, then soared by 71bps to 66.82% in 2022, then tumbled by -5745bps to 3905.63% in 2023, then plummeted by -79bps to 7004.6% in 2024, then surged by 100bps to 10.71% in 2025.
  • Per Business Quant, the three most recent readings for ARWR's EBT Margin are 10.71% (Q4 2025), 14.08% (Q3 2025), and 644.97% (Q2 2025).